130 related articles for article (PubMed ID: 9614864)
21. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
22. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.
Villeneuve JP; Condreay LD; Willems B; Pomier-Layrargues G; Fenyves D; Bilodeau M; Leduc R; Peltekian K; Wong F; Margulies M; Heathcote EJ
Hepatology; 2000 Jan; 31(1):207-10. PubMed ID: 10613747
[TBL] [Abstract][Full Text] [Related]
23. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
[TBL] [Abstract][Full Text] [Related]
24. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough.
Lee CH; Kim SO; Byun KS; Moon MS; Kim EO; Yeon JE; Yoo W; Hong SP
Gastroenterology; 2006 Apr; 130(4):1144-52. PubMed ID: 16618409
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
[TBL] [Abstract][Full Text] [Related]
26. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
[TBL] [Abstract][Full Text] [Related]
27. Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy.
Hacker HJ; Zhang W; Tokus M; Bock T; Schröder CH
Ann N Y Acad Sci; 2004 Jun; 1022():271-81. PubMed ID: 15251972
[TBL] [Abstract][Full Text] [Related]
28. Response to lamivudine treatment in children with chronic hepatitis B virus infection.
Hagmann S; Chung M; Rochford G; Jani M; Trinh-Shevrin C; Sitnitskaya Y; Neumann AU; Pollack H
Clin Infect Dis; 2003 Dec; 37(11):1434-40. PubMed ID: 14614664
[TBL] [Abstract][Full Text] [Related]
29. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.
Allen MI; Deslauriers M; Andrews CW; Tipples GA; Walters KA; Tyrrell DL; Brown N; Condreay LD
Hepatology; 1998 Jun; 27(6):1670-7. PubMed ID: 9620341
[TBL] [Abstract][Full Text] [Related]
30. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
[TBL] [Abstract][Full Text] [Related]
31. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
32. Long-term therapy of chronic hepatitis B with lamivudine.
Lau DT; Khokhar MF; Doo E; Ghany MG; Herion D; Park Y; Kleiner DE; Schmid P; Condreay LD; Gauthier J; Kuhns MC; Liang TJ; Hoofnagle JH
Hepatology; 2000 Oct; 32(4 Pt 1):828-34. PubMed ID: 11003630
[TBL] [Abstract][Full Text] [Related]
33. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
Tsubota A; Arase Y; Suzuki F; Kobayashi M; Matsuda M; Sato J; Suzuki Y; Akuta N; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Med Virol; 2004 May; 73(1):7-12. PubMed ID: 15042641
[TBL] [Abstract][Full Text] [Related]
34. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
Liang WF; Yang DH; Shen YH; Xie YJ; Zhao NF
Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
[TBL] [Abstract][Full Text] [Related]
35. [Determination of the lamivudine-resistant mutants of hepatitis B virus].
Gervain J; Papp I; Csöndes M; Nemesánszky E; Rácz I; Ribiczey P; Telegdy L; Tornai I; Weisz G
Orv Hetil; 2003 Jun; 144(25):1251-6. PubMed ID: 12901182
[TBL] [Abstract][Full Text] [Related]
36. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.
Dienstag JL; Schiff ER; Mitchell M; Casey DE; Gitlin N; Lissoos T; Gelb LD; Condreay L; Crowther L; Rubin M; Brown N
Hepatology; 1999 Oct; 30(4):1082-7. PubMed ID: 10498663
[TBL] [Abstract][Full Text] [Related]
37. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy.
Bourne EJ; Dienstag JL; Lopez VA; Sander TJ; Longlet JM; Hall JG; Kwiatkowski RW; Wright T; Lai CL; Condreay LD
J Viral Hepat; 2007 Jan; 14(1):55-63. PubMed ID: 17212645
[TBL] [Abstract][Full Text] [Related]
38. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
Chan HL; Wang H; Niu J; Chim AM; Sung JJ
Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.
Tassopoulos NC; Volpes R; Pastore G; Heathcote J; Buti M; Goldin RD; Hawley S; Barber J; Condreay L; Gray DF
Hepatology; 1999 Mar; 29(3):889-96. PubMed ID: 10051494
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneous response for a mammalian hepadnavirus infection to acyclovir: drug-arrested intermediates of minus-strand viral DNA synthesis are enveloped and secreted from infected cells as virion-like particles.
Tencza MG; Newbold JE
J Med Virol; 1997 Jan; 51(1):6-16. PubMed ID: 8986943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]